In the preceding three months, 11 analysts have released ratings for Moderna (NASDAQ:MRNA), presenting a wide array of perspectives from bullish to bearish. The table below offers a condensed view ...

Looking at options history for Moderna (NASDAQ:MRNA) we detected 32 trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish ...

Moderna (NASDAQ:MRNA), the biotech company known for its Spikevax COVID-19 vaccine, released its fourth-quarter earnings on Feb. 14. The results revealed significant financial challenges as the ...

Benzinga's options scanner just detected over 16 options trades for Moderna (NASDAQ:MRNA) summing a total amount of $1,134,726. At the same time, our algo caught 10 for a total amount of 1,113,875.

2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2024. "We have made progress in 2024 across our late-stage ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...

Looking at options history for Moderna (NASDAQ:MRNA) we detected 26 trades. If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish ...

We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

Our analysis of options history for Moderna (NASDAQ:MRNA) revealed 31 unusual trades. Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies.

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $2.69. In the year-ago period, the company had reported ...

Moderna (MRNA) came out with a quarterly loss of $2.50 per share versus the Zacks Consensus Estimate of a loss of $2.69. This compares to earnings of $0.55 per share a year ago. These figures are ...